• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).

作者信息

Xu Feng, Li Xiao, Chang Chunkang, He Qi, Zhang Zheng, Zhang Qianqiao, Wu Lingyun

出版信息

Leuk Res. 2009 Nov;33(11):e199-202. doi: 10.1016/j.leukres.2009.06.009. Epub 2009 Jul 9.

DOI:10.1016/j.leukres.2009.06.009
PMID:19592091
Abstract
摘要

相似文献

1
A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).一例伴有5号染色体长臂缺失（del(5q)）和20号染色体长臂缺失（del(20q)）的骨髓增生异常综合征患者对极短疗程来那度胺治疗的延迟但持久的反应及意外的克隆重新分布
Leuk Res. 2009 Nov;33(11):e199-202. doi: 10.1016/j.leukres.2009.06.009. Epub 2009 Jul 9.
2
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.来那度胺在 del(5q) 骨髓增生异常综合征疗效中的多效作用机制。
Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135.
3
The role of lenalidomide in the management of myelodysplasia with del 5q.来那度胺在伴有5号染色体长臂缺失的骨髓增生异常综合征治疗中的作用。
Br J Haematol. 2008 Feb;140(3):267-78. doi: 10.1111/j.1365-2141.2007.06910.x.
4
Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.伴 del(5q)骨髓增生异常综合征患者接受来那度胺治疗后的形态学分析：一项日本多机构研究。
Leuk Res. 2012 May;36(5):575-80. doi: 10.1016/j.leukres.2011.11.011. Epub 2011 Dec 15.
5
Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).来那度胺治疗伴有del(5q)和del(9q)的骨髓增生异常综合征患者的疗效及细胞遗传学完全缓解情况
Leuk Res. 2010 Jul;34(7):e169-72. doi: 10.1016/j.leukres.2009.12.015. Epub 2010 Jan 31.
6
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.来那度胺治疗伴有孤立性5号染色体长臂缺失（del(5q)）和JAK2 V617F突变的骨髓增生异常综合征患者的疗效
Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20.
7
Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.来那度胺治疗仅7天后，一名患有骨髓增生异常综合征且5号染色体长臂缺失患者的血液学和细胞遗传学反应。
Leuk Res. 2011 Sep;35(9):e175-6. doi: 10.1016/j.leukres.2011.05.020. Epub 2011 Jun 11.
8
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.停用来那度胺的del(5q)骨髓增生异常综合征患者的长期输血独立性
Leukemia. 2012 Apr;26(4):855-8. doi: 10.1038/leu.2011.268. Epub 2011 Sep 30.
9
Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Ann Hematol. 2012 Feb;91(2):309-10. doi: 10.1007/s00277-011-1263-7. Epub 2011 May 28.
10
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.接受来那度胺治疗后未能获得持续红细胞或细胞遗传学缓解的 del(5q) MDS 患者，其克隆进化和 AML 进展的风险增加。
Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.

引用本文的文献

1
Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).来那度胺对伴有5号染色体长臂缺失的骨髓增生异常综合征患者的疗效：来自希腊国家骨髓增生异常综合征与再生障碍性贫血综合征登记处（EAKMYS）的真实世界数据。
Cancers (Basel). 2025 Apr 22;17(9):1388. doi: 10.3390/cancers17091388.
2
Durable hematological and major cytogenetic response in a patient with isolated 20q deletion myelodysplastic syndrome treated with lenalidomide.来那度胺治疗孤立性20q缺失骨髓增生异常综合征患者的持久血液学和主要细胞遗传学缓解
Case Rep Oncol Med. 2014;2014:949515. doi: 10.1155/2014/949515. Epub 2014 Feb 12.